Systemic expression of Alu RNA in patients with geographic atrophy secondary to age-related macular degeneration

Yoshida H., Matsushita T., Kimura E., Fujita Y., Keany R., Ikeda T., Toshimori M., Imanaka T., Nakamura M.

2019
PLoS ONE

View publication

Therapeutic Area

Back of the eye (BOTE)
Technology

Other

Affiliations

Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Research and Development Division, Santen Inc., Emeryville, CA, United States

Related Publications

STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.

Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.

View all Back of the eye (BOTE) publications